switching from semaglutide to tirzepatide dosing Switching from semaglutide to tirzepatide

Competition Picture BMO Capital Markets analyst Evan Seigerman said investors will follow the evolution of the market in Canada closely as a test case to see if and how generics can compete with branded peptides [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/]

Compounded versions available through Omzo are not FDA-approved as finished products

After I sold my first company, and I had like two and a half million dollars in the bank, I still kept a budget

Results Extension analyses included 327 participants

Zepbound is $349 for the lowest monthly dose, going up to $499 for higher doses

This two-step gatekeeping process excludes many eligible patients and extends timelines significantly